In Brief: Merck's Mectizan
Executive Summary
Merck's Mectizan: Ivermectin 6 mg tablet is "approvable" as of Oct. 8 for strongyloidiasis and onchocerciasis (river blindness) parasitic infections. Merck filed an NDA for the indications in March. About 10,000 cases of strongyloidiasis infections are reported in the U.S. annually...